A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety,
tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with
treatment of malignant pleural effusions caused by NSCLC.